Litcius/Paper detail

Squamous differentiation is a potential biomarker predicting tumor progression in patients treated with pembrolizumab for urothelial carcinoma

Yu Miyama, Teppei Morikawa, Jimpei Miyakawa, Yuichi Koyama, Taketo Kawai, Haruki Kume, Tetsuo Ushiku

2021Pathology - Research and Practice16 citationsDOI

Topics & Concepts

PembrolizumabMedicineBiomarkerOncologyProgressive diseaseImmunohistochemistryCancerInternal medicineTumor progressionPathologyDiseasePathologicalImmunotherapyCancer researchBiologyBiochemistryBladder and Urothelial Cancer TreatmentsCancer Immunotherapy and BiomarkersUrinary and Genital Oncology Studies